A pre-specified meta-analysis including all the seven clinical trials that constituted the clinical development program of tirzepatide (SURPASS) demonstrated its CV safety in patients with T2DM in terms of not increasing the risk of major adverse CV events (MACE)
These benefits have been demonstrated in large, well-designed cardiovascular outcome trials, including: Liraglutide (Victoza) the LEADER trial , which showed a significant reduction in cardiovascular death and all-cause mortality Semaglutide (Ozempic) the SUSTAIN-6 trial , demonstrating fewer major adverse cardiovascular events, particularly stroke Dulaglutide (Trulicity) the REWIND trial , which showed a significant reduction in major cardiovascular events even in people without established cardiovascular disease Tirzepatide (Mounjaro) cardiovascular outcome data from the SURPASS-CVOT programme are emerging, with early results suggesting cardiovascular benefit compared with insulin therapy These cardiovascular effects are a key reason why GLP-1based therapies are now recommended earlier in the treatment pathway for people with type 2 diabetes who have established heart disease or are at high cardiovascular risk
Stimulates the production of collagen and elastin
This helps define the jawline, reduce puffiness, and lift sagging muscles
But with a brain fixated on food, "I thought I could never go 16 or 18 hours without eating," she recalls
all of which ensure the efficient production of proteins necessary for muscle growth
